Ipsen will pay $111m in cash and equity upfront to gain the global rights, exclu...
Sandoz launched the biosimilar of J&J’s Stelara in Europe in partnership with Sa...
A Phase II study for ConSynance’s triple monoamine reuptake inhibitor CSTI-500 i...
The US FDA has expanded approval to BioMarin Pharmaceutical's BRINEURA to includ...
The UK NICE has issued final guidance endorsing Boehringer Ingelheim’s tenectepl...
Dren Bio has entered a strategic partnership with Novartis Pharma to develop the...
Telix is eyeing an expansion of the diagnostic imaging indications for its asset...
Final podcast in Sterling's series, examining how a range of factors influence t...
Agilent Technologies has announced a definitive agreement for the acquisition of...
Samsung Bioepis has announced the approval of EPYSQLI BLA by the US Food and Dru...
Johnson & Johnson is seeking approval for SPRAVATO for treatment-resistant depre...
Grünenthal has announced the acquisition of Valinor Pharma and its opioid-induce...
UNAIDS executive director Winnie Byanyima called upon Gilead to allow generics t...
The latest resubmission addressed remaining CMC concerns, with the FDA confirmin...
The US government will not give bluebird bio the opportunity to offer fertility ...
A Phase II trial with Johnson and Johnson (J&J) and Addex’s epilepsy drug had fa...
